Randomised clinical trials have been the mainstay of pharmaceutical product development for decades, but will they be designed and carried out the same way in future? With trials tipped to get smaller and patient selection more complex as pharma’s blockbuster model is dismantled, interactive technologies, adaptive designs and new ways to recruit and monitor patients will come to the fore.
20-Jun-2012 - Outsourcing-Pharma.com presents a roundup of eClinical news, including developments at Parexel, Datatrak, and MedNet.
14-Jun-2012 - Regulation of clinical trials in emerging markets is now too strict and is prompting sponsors and CROs to adopt “one-size-fits-all” designs, according to a new study.
11-Jun-2012 - Outsourcing is no longer a need but a "must" to lift the flat biologics discovery industry, according to a new analysis.
06-Jun-2012 - Catalent has upgraded its North Carolina, US, sterile development and analytics plant to increase its aseptic fill-finish activities four-fold in a bid to boost its integrated biologics offering.
05-Jun-2012 - Creation of long-term biopharma relationships is hindered by continued pursuit of short-term gains, according to Quintiles’ New Health Report.
04-Jun-2012 - Catalent has sold its US commercial packaging business to Frazier Healthcare as part of plans to focus on “innovative pipelines”.
31-May-2012 - The use of home visits in clinical trials could raise the chances of regulatory approval, according to ResearchNurses.co.
30-May-2012 - Including home visits in clinical trial designs could be the key to patient retention, according to ResearchNurses.co.
28-May-2012 - More than a third of patient recruitment will be done in emerging markets in the future, predicts Chiltern CEO Glenn Kerkhof.
24-May-2012 - A host of Big Pharma firms have come together to participate in a new forum in a bid to boost patient recruitment activities in emerging markets.
22-May-2012 - ‘CROs: look at the entire portfolio, not just the individual project, when planning clinical studies,’ says DIA’s adaptive design scientific working group.
22-May-2012 - Quanticate says it will eliminate unnecessarily “complicated spreadsheets” in clinical trial data analysis after integrating a new simplified web-based program into its own.
02-May-2012 - Chiltern has set up a legal entity in Taiwan that will allow it to establish its own local clinical research operations for the first time.
16-Apr-2012 - Almac says the adoption of ‘lean six sigma’ was the right move for its clinical technologies business, even taking higher initial training costs into account.
16-Apr-2012 - Designing trials around patients’ habits is the key to success in patient compliance, according to online recruitment specialist Rebar Interactive.
12-Apr-2012 - Outsourcing-Pharma presents a roundup of eClinical news, including an update at Medidata to drive growth in 2012.
05-Apr-2012 - Regulatory reform was the name of the game at this year’s DIA Euromeeting in Denmark.
05-Apr-2012 - GE Healthcare has bought a nucleic acid technology CRO, SeqWright, to add to its range of genomic services.
04-Apr-2012 - Catalent wants to build on its European expansions by replicating the end-to-end drug development services model in emerging markets.
04-Apr-2012 - Niche CRO Proteome Sciences is poised for triple-digit sales growth as its biomarker business takes off, an investment research firm said.
29-Mar-2012 - “Less bureaucracy and more research” was the Danish Minister of science and innovation’s message to regulators at this week's DIA Euromeeting.
22-Mar-2012 - The FSP model is “alive and well” with inVentiv, INC Research, and others in the hunt for sizable deals with big pharma companies.
21-Mar-2012 - Formac Pharmaceuticals and WR Grace say their silica platform can improve the formulation selection process for poorly soluble APIs (active pharmaceutical ingredients).
20-Mar-2012 - inVentiv Health will stump up $50m for contract staffing firm Kforce Clinical Research (KCR) to ramp up its funcatiuonal service provider (FSP) business.
20-Mar-2012 - The virtual development model needs a string of successes or blockbusters to convince the ‘herd’ of its merits, an expert said.